- Home
- SQFTW vs GNLX Comparison
SQFTW vs GNLX Comparison
Compare SQFTW & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQFTW | GNLX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 202.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SQFTW | GNLX |
|---|---|---|
| Price | $0.04 | $4.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | N/A | ★ 140.8K |
| Earning Date | N/A | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $1.99 |
| 52 Week High | N/A | $8.54 |
Technical Indicators
Market Signals| Indicator | SQFTW | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 40.57 |
| Support Level | $0.03 | $4.20 |
| Resistance Level | $0.03 | $4.37 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 97.62 | 32.35 |
Price Performance
Historical ComparisonAbout SQFTW Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.